Category: Medicine

The keto diet may offer significant benefits for individuals suffering from anorexia nervosa, according to new research from UC San Diego.

New research from the UC San Diego School of Medicine suggests that the ketogenic diet may help alleviate symptoms of anorexia nervosa. The study, published in the journal Nature, involved 22 women aged 18 to 45 who had a history of anorexia nervosa and a body mass index (BMI) above 17.5.

Anorexia nervosa (AN) is a serious psychiatric disorder characterized by severe food restriction and low body weight. Individuals with this condition often experience body dissatisfaction, an intense fear of eating, and a preoccupation with body shape and size, even after weight restoration.

The participants in the study adhered to a ketogenic therapy plan for 14 weeks, aiming for a diet composed of 70% fat, 20% protein, and 10% carbohydrates. The objective was to maintain weight while inducing nutritional ketosis, a metabolic state where the body produces and utilizes ketones for energy due to low carbohydrate intake.

Throughout the study, researchers monitored participants through ketone testing, weekly weight checks, symptom questionnaires, and nutritional and psychiatric support. Among the 18 participants who completed the study, improvements were noted in various areas related to eating disorder symptoms, including restraint, depression scores, and concerns regarding eating, shape, and weight.

Overall scores on the Eating Disorder Examination Questionnaire (EDE-Q) showed significant improvement, with 72% of participants scoring within the recovered or normal range. Importantly, participants’ body weight remained stable, and no BMI fell below the critical threshold of 17.5.

Those who continued to follow the ketogenic therapy three months post-intervention exhibited slightly better EDE-Q scores, indicating ongoing benefits from the dietary approach. The study authors concluded that ketogenic dietary therapy is “well-tolerated” and shows “potential efficacy” in reducing symptoms of anorexia nervosa among adults who are mildly underweight or weight-restored.

Despite these promising findings, the authors acknowledged that the small sample size, which predominantly consisted of White females, limits the generalizability of the results. They emphasized the need for future research to replicate these findings in more diverse populations and to incorporate objective assessments of brain function, such as metabolic PET imaging, to evaluate brain glucose metabolism.

Lead study author Dr. Guido Frank, a professor of psychiatry at UC San Diego School of Medicine, has dedicated over 25 years to studying and treating patients with anorexia. He initiated this study to expand treatment options for this high-risk population, stating that new approaches to anorexia nervosa are “urgently” needed.

Dr. Frank noted, “Our work with ketogenic therapy looks beyond standard therapies and potentially at the underlying physiology of the disorder.” He highlighted the growing evidence linking anorexia nervosa to neurometabolic dysfunction, expressing hope that direct metabolic intervention could help regulate neural function and address the psychological symptoms experienced by patients.

As the conversation around effective treatments for anorexia nervosa continues, this research opens the door to exploring alternative dietary interventions that may provide relief for those affected by this challenging condition, according to Fox News.

A new mRNA melanoma vaccine developed by Merck and Moderna has demonstrated significant long-term benefits, reducing the risk of cancer recurrence or death by nearly 50% over five years.

A novel mRNA melanoma vaccine, known as intismeran autogene, has shown promising results in reducing melanoma risk over a five-year period. This personalized cancer therapy, developed through a collaboration between Merck and Moderna, was presented during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.

The findings stem from the phase 2b KEYNOTE-942 study, which reported that the combination of intismeran autogene and the immunotherapy drug KEYTRUDA (pembrolizumab) reduced the risk of cancer recurrence or death by 49% compared to patients who received pembrolizumab alone.

Researchers analyzed data from 157 patients diagnosed with high-risk stage 3 and 4 melanoma, all of whom had undergone surgical removal of their tumors. Participants were divided into two groups: one received the combination therapy, while the other was treated solely with pembrolizumab. The results indicated that the benefits of the combination therapy were “sustained and durable over time.”

Intismeran autogene is engineered using mutations identified in a patient’s own tumor, aiming to educate the immune system on how to recognize and attack the cancer cells effectively.

According to the researchers, the personalized mRNA vaccine combined with KEYTRUDA is “well-tolerated” and has a “manageable” safety profile. Common side effects reported included fatigue, injection-site pain, chills, fever, and headache. Notably, there were no new long-term safety concerns or severe vaccine-related adverse events reported.

The combination therapy is currently undergoing evaluation in a phase 3 study, which represents the final confirmation stage before potential approval.

In a press release from Merck in January, Dr. Kyle Holen, senior vice president and head of development for oncology and therapeutics at Moderna, emphasized the significance of the data, stating it highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.” He added that the company continues to invest in its oncology platform due to encouraging outcomes that demonstrate mRNA’s potential in cancer care.

Dr. Marjorie Green, senior vice president and head of oncology global clinical development at Merck Research Laboratories, remarked on the importance of the findings, noting that many patients with stage 3 or 4 melanoma face a “significant risk of recurrence following surgery.” She described the demonstration of the longer-term potential of intismeran autogene and KEYTRUDA to reduce recurrence risk as a “meaningful milestone.”

The company has cited encouraging five-year follow-up data and is looking forward to results from the upcoming late-stage INTerpath trial, which will evaluate the combination therapy in several difficult-to-treat cancers.

As the field of cancer treatment continues to evolve, the promising results of the intismeran autogene vaccine may represent a significant step forward in the fight against melanoma and potentially other cancers, according to Fox News.

Dr. Samir M. Parikh, an esteemed Indian American nephrologist, has been appointed Chair of the Department of Internal Medicine at UT Southwestern Medical Center, effective June 15.

Dr. Samir M. Parikh, a prominent Indian American nephrologist, is set to assume the role of Chair of the Department of Internal Medicine at UT Southwestern Medical Center in Dallas, Texas, starting June 15. In this prestigious position, he will oversee a department comprising nearly 900 faculty members and manage a residency program that ranks as the second largest in the nation.

Under Dr. Parikh’s leadership, the department will benefit from substantial funding, with more than $108 million allocated from the National Institutes of Health (NIH) for the fiscal year 2025. He will also hold the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy Sr. Chair in Molecular Nephrology, as announced in a university release.

Currently, Dr. Parikh serves as a Professor and Chief of the Division of Nephrology at UT Southwestern, a position he has held since joining the institution in 2021. He also has a secondary appointment in the Department of Pharmacology.

Dr. Parikh earned his bachelor’s degree in chemistry from Harvard College, graduating magna cum laude. He obtained his medical degree from Vanderbilt University and completed his internal medicine residency, along with research and clinical fellowships in nephrology, at Beth Israel Deaconess Medical Center. There, he was recognized as a Harvard Medical School Fellow in General Medicine.

His academic career began at Harvard, where he advanced to the position of Professor of Medicine. He also served as Co-Director of the Center for Vascular Biology Research and held the role of Associate Vice Chair for Research in the Department of Medicine at Beth Israel Deaconess.

In his clinical practice, Dr. Parikh specializes in acute kidney injury and chronic kidney disease. His research over the past two decades has concentrated on the mechanisms of aging in the vasculature, kidneys, and energy metabolism.

Dr. Parikh’s laboratory has garnered over $40 million in funding from the NIH and other sources, and his research findings have been published in prestigious journals, including *Science*, *Nature*, *Nature Medicine*, and *Cell Metabolism*.

In addition to his research and clinical work, Dr. Parikh is an elected member of several esteemed organizations, including the American Society for Clinical Investigation, the American Association of Physicians, and the American Clinical and Climatological Association.

His accolades include the NIH Outstanding Investigator Award, the Donald W. Seldin Young Investigator Award from both the American Society of Nephrology and the American Heart Association, as well as the STARs Award from the University of Texas System. Currently, he serves as the 59th President of the American Society of Nephrology (ASN).

During his presidency, ASN has made significant strides in advancing national research priorities through the Transforming Kidney Health Research initiative and has played a pivotal role in advocacy efforts that led to the passage of the Honoring our Living Donors (HOLD) Act.

Dr. W. P. Andrew Lee, Executive Vice President for Academic Affairs and Provost and Dean of UT Southwestern Medical School, expressed confidence in Dr. Parikh’s leadership. “Dr. Parikh’s commitment to all areas of our mission will further the Department of Internal Medicine and our institution’s national reputation for providing excellent clinical care, advancing meaningful research, and fostering a unique environment for biomedical education,” he stated.

Dr. Parikh’s appointment marks a significant milestone for UT Southwestern, as the institution continues to enhance its reputation as a leading center for medical education and research.

For more information, please refer to the official announcement from UT Southwestern.

Dr. Anushree Vichare has been appointed interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University, effective July 1.

Dr. Anushree Vichare, an accomplished Indian American researcher, has been named the interim director of the Fitzhugh Mullan Institute for Health Workforce Equity at George Washington University. She will officially assume her new role on July 1, succeeding Dr. Patricia “Polly” Pittman, who is retiring after co-founding the institute 11 years ago and serving as its director since 2020.

Vichare, an associate professor, began her academic journey in India, where she earned her Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from MGM Medical College. She later moved to the United States to further her education, obtaining a Master of Public Health in epidemiology and a PhD in Healthcare Policy and Research from Virginia Commonwealth University.

Her extensive academic portfolio reflects her training and expertise, focusing on how Medicaid policies influence healthcare access, utilization, and outcomes for low-income populations. At George Washington University, Vichare’s work in the Department of Health Policy and Management examines the composition, diversity, and geographic distribution of health workers and their impact on the quality of care available to underserved communities.

Dr. Pittman praised Vichare’s contributions, stating, “Anushree has been an integral part of the leadership team, has a deep commitment to our mission and work, and, importantly, is adored by everyone who has the chance to work with her.”

In her current role, Vichare serves as an investigator on several externally funded research initiatives at the Mullan Institute. Her recent scholarship includes analyzing maternal health services, evaluating care delivery for Medicaid beneficiaries diagnosed with cancer, and exploring the impact of patient-clinician concordance on primary care utilization.

In addition to her research, Vichare co-leads the Health Workforce Diversity Initiative under the Social Mission Alliance at the institute. Her previous experience in health policy includes serving as the director of quality improvement for the American Gastroenterological Association, where she specialized in developing clinical performance metrics and quality measures for colonoscopy care.

University officials have indicated that Vichare will guide the strategic operations of the institute while a national search for a permanent director is conducted. Her leadership is expected to continue advancing the institute’s mission of promoting health workforce equity.

According to a university release, Vichare’s appointment reflects the institution’s commitment to maintaining strong leadership during this transitional period.

Cancer survivors practicing yoga experience significant improvements in mood, anxiety, and fatigue, according to a recent clinical trial published in the Journal of Clinical Oncology.

Cancer survivors often face ongoing physical and emotional challenges long after their treatment has concluded. A recent clinical trial has found that yoga may play a crucial role in alleviating some of these issues, particularly insomnia, fatigue, and mood disturbances that many survivors endure after remission.

The study, funded by the National Cancer Institute, involved 410 participants, including 204 cancer survivors receiving standard survivorship care alone and 206 survivors who incorporated the Yoga for Cancer Survivors (YOCAS) program into their treatment. The majority of participants were female breast cancer survivors.

YOCAS is a four-week intervention that combines two types of yoga: hatha, which is more active and traditional, and restorative, which is gentler and more passive. Both styles emphasize slow movements, breathing exercises, and mindfulness, as noted by the American Society of Clinical Oncology (ASCO).

During the trial, participants in the YOCAS group practiced yoga for an average of 180 minutes each week across three sessions. At the end of the study, those in the YOCAS group reported significant improvements in mood, anxiety, and fatigue, while the standard care group showed no such benefits.

“Additionally, improvements in insomnia stemming from YOCAS yoga may be mediated by changes in overall mood disturbance and fatigue,” the researchers stated in their findings.

Dr. Fumiko Chino, a cancer researcher and associate professor in breast radiation oncology at MD Anderson Cancer Center, emphasized the importance of this study. “It offers survivors, who are likely already managing multiple medications, a non-pharmaceutical solution for reducing four different side effects at once,” she said.

Dr. Timothy Pearman, director of supportive oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, expressed that he was not surprised by the study’s results. “Yoga is one of the most widely studied and validated interventions for managing cancer-related fatigue, mood disturbance, and overall physical health,” he noted.

Pearman shared that his wife, Jenny Finkel, is a yoga teacher who received her continuing education at Duke University’s integrative medicine program, which specializes in yoga for cancer patients. He highlighted the accessibility of yoga, stating, “All you need is a mat and someone to show you how to do it.” He also mentioned that yoga is highly adaptable, making it suitable for individuals with significant physical impairments.

In addition to addressing mood and fatigue, Pearman pointed out that yoga can help mitigate other physical symptoms related to cancer treatment, such as osteoporosis, an increased risk of cardiac problems, and issues with balance and stamina.

Shari Botwin, a licensed clinical social worker based in Pennsylvania and a thyroid cancer survivor, has seen firsthand the transformative effects of yoga. Specializing in trauma recovery, she noted that many cancer survivors face emotional challenges, including depression and survivor’s guilt. Botwin believes that yoga not only provides physical relief but also fosters a supportive environment among peers, some of whom are also cancer thrivers.

Botwin added that yoga can assist survivors in reframing their thoughts, especially those who have lost parts of their bodies due to cancer. “It supports us in moving into a place of self-compassion rather than shame and self-hatred,” she explained.

While yoga has shown promising benefits, Pearman emphasized that almost any type of exercise can be advantageous for cancer survivors. He advises his patients to engage in activities they enjoyed prior to their diagnosis. Furthermore, he noted that free yoga classes tailored for cancer survivors are widely available through various non-profit organizations.

As research continues to unveil the benefits of yoga for cancer survivors, it becomes increasingly clear that this practice can play a vital role in enhancing the quality of life for those navigating the aftermath of cancer treatment, according to Fox News Digital.

Former Attorney General Pam Bondi’s recent diagnosis of thyroid cancer highlights the importance of understanding the disease and its prognosis.

Former Attorney General Pam Bondi was diagnosed with thyroid cancer shortly after her departure from the Department of Justice last month. Bondi, 60, left her position in early April and is currently undergoing treatment and recovering, according to reports.

The thyroid is a butterfly-shaped gland located in the neck that produces hormones essential for regulating metabolism, energy levels, and the proper functioning of various organs, including the brain, heart, and muscles. The American Thyroid Association emphasizes the gland’s vital role in maintaining overall health.

Thyroid cancer, while relatively uncommon compared to other types of cancer, is still a significant health concern. As of 2023, more than one million individuals in the United States are living with the disease. The National Cancer Institute (NCI) projects that approximately 45,260 new cases will be diagnosed in 2026.

This form of cancer is more prevalent in women, but it can affect individuals of all genders. Risk factors include a family history of the disease, age (with those between 25 and 65 being more susceptible), and exposure to radiation.

Symptoms of thyroid cancer can manifest as lumps or swelling in the neck, difficulty breathing or swallowing, hoarseness, and pain during swallowing. Individuals experiencing these symptoms are advised to seek medical attention promptly.

If thyroid cancer is suspected, diagnosis can involve several methods. A laryngoscopy allows doctors to examine the voice box using a mirror or a thin tube-like instrument equipped with a light and lens. Blood tests can measure hormone levels, providing additional indicators of thyroid cancer. Imaging techniques such as ultrasounds and CT scans are also employed to identify tumors.

Treatment options for thyroid cancer typically include surgery, radiation, chemotherapy, and hormone therapy. A newer approach, immunotherapy, is currently being tested in clinical trials. According to Dr. Marc Siegel, a senior medical analyst at Fox News, surgery is the primary treatment method, often followed by regular monitoring and thyroid hormone replacement therapy.

In cases where the entire thyroid gland must be removed, patients will require hormone replacement to compensate for the loss of natural thyroid function. Dr. Siegel notes that radioactive iodine may be used in more aggressive cases, although it is not always necessary.

The prognosis for thyroid cancer is generally favorable, largely depending on the cancer’s response to treatment. Some types of thyroid cancer are milder and grow more slowly than others. The stage of the cancer at diagnosis also plays a crucial role in determining outcomes.

The most optimistic scenario occurs when a surgeon can completely excise the tumor during surgery. Additionally, doctors will consider whether this is a new diagnosis or a recurrence of previously treated cancer.

As Bondi navigates her treatment journey, her case underscores the importance of awareness and understanding of thyroid cancer and its implications for those diagnosed.

For more information on thyroid cancer and its treatment options, consult resources provided by the National Cancer Institute and other health organizations.

According to Fox News, Bondi’s diagnosis serves as a reminder of the need for vigilance regarding health and wellness.

Kyle Busch’s death was attributed to severe pneumonia that progressed to sepsis, highlighting the dangers of untreated respiratory infections, according to his family.

Kyle Busch, the two-time NASCAR Cup champion, passed away at the age of 41 due to severe pneumonia that escalated into sepsis, as confirmed by a statement from his family. The announcement, made on Saturday, detailed that Busch died on Thursday following a brief hospitalization for what was described as a “severe illness.”

The family’s statement explained, “The medical evaluation provided to the Busch Family concluded that severe pneumonia progressed into sepsis, resulting in rapid and overwhelming associated complications.” This tragic case emphasizes the serious risks associated with pneumonia, particularly when symptoms are ignored or worsen quickly.

Pneumonia is a respiratory infection that fills the lungs with fluid, making it difficult to breathe. It can be caused by various pathogens, including bacteria, viruses, or fungi. Common symptoms of pneumonia include cough, fever, chills, chest pain, and shortness of breath.

Prior to his death, Busch reportedly suffered from a sinus infection that deteriorated into pneumonia. Dr. Marc Siegel, a senior medical analyst for Fox News, noted that “this upper respiratory sinus infection progressed to pneumonia.” He further explained that bacterial pneumonia is typically more severe than its viral counterpart.

Dr. Siegel also pointed out that the physical stress associated with racing simulators—designed to replicate the intense G-forces experienced by drivers—could exacerbate already inflamed lungs during the recovery process from pneumonia, although direct research on this topic remains limited.

In severe cases, pneumonia can lead to the infection spreading into the bloodstream, resulting in a life-threatening inflammatory response known as sepsis. This is particularly dangerous for vulnerable patients or when treatment is delayed. Sepsis can quickly lead to tissue damage, organ failure, and even death if not addressed promptly.

<p”The body reacts to this severe lung infection by making inflammatory chemicals. It’s the immune system revving up,” Dr. Siegel explained. “But as with many things in the body, the immune system can hurt more than help.” As sepsis progresses, it can cause a drop in blood pressure and hinder the delivery of oxygen to the body’s tissues, potentially resulting in lactic acidosis—a dangerous buildup of lactic acid in the bloodstream.

Organ failure is a significant risk, particularly affecting the kidneys, according to Dr. Siegel. “The kidneys fail, toxins from the kidneys build up, blood pressure goes down, fever goes up, the lungs fail—something called ARDS,” he warned. Acute respiratory distress syndrome (ARDS) occurs when inflammation causes fluid to leak into the lungs, making it difficult for oxygen to reach the bloodstream.

Common warning signs of sepsis include confusion, rapid breathing, extreme weakness, low blood pressure, fast heart rate, and bluish or mottled skin, as noted by the Centers for Disease Control and Prevention (CDC).

Doctors stress that sepsis is a medical emergency, as patients can deteriorate rapidly within hours. Those at higher risk for severe pneumonia and sepsis include older adults, smokers, individuals with chronic lung diseases, diabetes, weakened immune systems, or those who have recently experienced viral infections.

This tragic incident serves as a reminder of the potential severity of pneumonia and the importance of seeking timely medical attention for respiratory infections, especially for those at greater risk.

According to Fox News, the circumstances surrounding Kyle Busch’s death highlight the critical need for awareness and prompt treatment of pneumonia and its complications.

Two Maryland residents are under monitoring for potential hantavirus exposure after sharing a flight with an infected passenger from the MV Hondius cruise ship.

Two residents of Maryland are currently being monitored for possible exposure to hantavirus, as reported by the Maryland Department of Health. Health officials stated that these individuals were on a flight that included a passenger from the MV Hondius cruise ship, who has been confirmed to be infected with hantavirus.

Authorities are taking these precautionary measures to ensure public safety, although they emphasize that the risk to the general public in Maryland remains “very low.” State health officials are closely observing the situation.

It is important to note that the two Maryland residents were not aboard the MV Hondius cruise ship; rather, they were on a flight with a passenger who had contracted the virus. The Maryland Department of Health has opted not to disclose further details about the residents in order to protect their privacy.

The monitoring process will continue throughout the virus’s incubation period, which can last from four to 42 days. Officials have stated that individuals who do not exhibit symptoms are not considered infectious.

Maryland has not reported any cases of hantavirus since 2019, and the Andes virus, which is associated with the recent cruise ship incident, has never been identified in the state. Health authorities are coordinating efforts with federal and international partners as they navigate this evolving situation.

Hantavirus is primarily transmitted through contact with infected rodents, but the strain linked to the cruise ship—the Andes virus—is unique in that it can be transmitted from person to person. The Centers for Disease Control and Prevention (CDC) has confirmed that hantaviruses found throughout the United States do not spread between individuals.

Hantavirus pulmonary syndrome (HPS) is a rare but serious infectious disease that begins with flu-like symptoms and can rapidly develop into severe lung and heart complications. Various strains of hantavirus can lead to this illness, also referred to as hantavirus cardiopulmonary syndrome, according to the Mayo Clinic.

Initial symptoms of HPS may include fatigue, fever, and muscle aches. Approximately half of all patients also report headaches, dizziness, chills, and gastrointestinal issues such as nausea, vomiting, and diarrhea. The CDC indicates that HPS carries a nearly 40% fatality rate for those infected.

Similar cases of hantavirus have been documented in states such as Arizona, California, and Georgia, raising awareness about the potential risks associated with this disease.

As the situation develops, health officials continue to monitor the residents and provide updates to the public, ensuring that safety measures are in place to mitigate any potential risks.

For more information on hantavirus and its effects, residents are encouraged to consult resources from the Maryland Department of Health and the CDC.

According to Fox News, health officials remain vigilant as they assess the situation and keep the public informed.

High-dose vitamin B3 may enhance immune function and slow the progression of glioblastoma, with 82% of trial patients showing no disease progression after six months, according to a recent study.

High-dose vitamin B3, commonly known as niacin, may significantly boost immune function and improve short-term disease control in patients with glioblastoma when used alongside standard therapies, according to early preclinical studies.

Glioblastoma is a highly aggressive and fast-growing brain cancer that originates from cells in the brain and spinal cord. Previous laboratory experiments conducted on mice indicated that niacin could extend survival rates. Researchers at the University of Calgary sought to determine whether these benefits could also be observed in humans.

The clinical trial included 24 patients diagnosed with glioblastoma, a condition that typically has a median survival rate of approximately 12 to 18 months. Remarkably, six months after receiving niacin in conjunction with standard treatments—surgery, radiation, and chemotherapy—82% of the patients exhibited no disease progression. This is a notable increase compared to the typical 54% of patients who experience no progression under standard treatment alone, as reported in the study’s press release.

Additionally, niacin was found to restore functionality in weakened immune cells, enhancing their ability to target and eliminate tumor cells. The findings, which highlight a 28% improvement in disease progression, were published in the Journal of Neuro-Oncology.

“Normally, the immune system attempts to counter and prevent tumor growth; however, glioblastoma actively suppresses the immune response,” said Dr. Wee Yong, PhD, a neuroscientist involved in the study. “Niacin treatment rejuvenates immune cells so they can perform their essential functions: attacking and destroying cancer cells. I view this as an ongoing ‘battle for the brain.’”

Looking ahead, the research team plans to enroll an additional 24 patients by the end of 2026 or early 2027 for the next phase of the trial, which will focus on assessing niacin’s safety and its effects on immune system activation.

Dr. Marc Siegel, a senior medical analyst at Fox News, noted that previous studies have demonstrated that vitamin B3 can reduce inflammation and enhance immune function. “Vitamins, including the B vitamins—especially niacin—are often underrecognized as immune boosters,” he stated, although he was not involved in the study.

Despite these promising early results, the researchers have urged caution regarding the implications of their findings. “Glioblastoma is the most aggressive brain cancer in adults, and patient survival rates have not significantly improved in the past two decades,” said lead study author Roldan Urgoiti, a clinical associate professor at the CSM. “While any potential treatment that may help should be explored, it requires strict protocols and safety monitoring.”

The study’s limitations include its small sample size, short follow-up period, and the absence of a randomized control group. The researchers emphasized the need for larger, controlled trials to verify their findings.

Furthermore, the researchers cautioned that high doses of vitamins can pose health risks, and any supplementation should be closely monitored by healthcare professionals. Dr. Siegel also acknowledged that niacin can have side effects, such as skin flushing. “While there may be a small impact here, this information is useful, though it is clearly not a cure,” he added.

As the research progresses, the scientific community remains hopeful that niacin could play a role in enhancing treatment options for glioblastoma patients, but further investigation is essential to fully understand its potential benefits and risks.

According to Fox News, the ongoing exploration of vitamin therapies in cancer treatment represents a promising avenue for improving patient outcomes in the face of challenging diagnoses.

Clinical trials are essential to medical advancements, yet misconceptions and lack of awareness hinder participation, impacting the development of new treatments and therapies.

Clinical trials serve as the cornerstone of medical advancements, leading to breakthroughs in cancer treatments, vaccines, and diagnostic tools. However, many people remain unaware of their significance until faced with a serious health diagnosis. This gap in knowledge, combined with prevalent misconceptions, can have serious consequences. It can slow the progress of promising treatments, prevent patients from accessing cutting-edge care, and limit the applicability of trial results due to a lack of diverse participants.

One of the most common misconceptions surrounding clinical trials is that they are only for patients with severe illnesses, leading to the belief that medical professionals recommend trials only when there is little hope left. Additionally, the fear of being treated as a “guinea pig” is a widespread concern that transcends various patient populations, regardless of their previous research experiences. Many potential participants worry that they might receive a placebo, rendering their involvement ineffective.

According to the clinical center at the National Institutes of Health (NIH), only about 1% of the U.S. population participates in clinical trials. Paradoxically, nearly 80% of the general public holds a positive view of clinical research, despite these fears and misconceptions. Professor Lisa Goldman Rosas, an expert in Epidemiology and Population Health at Stanford’s School of Medicine, notes, “Community mistrust and lack of awareness are major barriers to participation in clinical trials, particularly in underrepresented communities. History plays a big role, and we have to work hard to educate the community and gain people’s trust.”

So, what exactly is a clinical trial? Clinical trials are meticulously designed research studies aimed at testing new medical interventions—such as drugs, devices, procedures, or preventive measures—to assess their safety and effectiveness before they become widely available. These trials are crucial for advancing medical research and developing new treatments. Every prescribed medication in the U.S. has undergone this rigorous testing process, which can take a decade or longer before receiving approval from the Food and Drug Administration (FDA).

In clinical trials, human subjects are assigned to one or more interventions, which may include a placebo or other control, to evaluate the effects on health-related biomedical or behavioral outcomes. Each study follows a predefined, reviewed, and approved process outlined in a written protocol, detailing how subjects will be assigned to different groups or “arms” of the trial.

A fundamental principle in clinical trial design is that the welfare of participants must always take precedence over the interests of science and society. Ethical considerations are paramount, and all trial protocols undergo ethical review and oversight by independent Institutional Review Boards, as mandated by federal law for all clinical research involving human subjects in the U.S. and many other countries.

There are various types of clinical trials. Approximately 25% are observational, where researchers monitor and record data without intervening. The landmark Framingham Heart Study, which began in 1948, is a prime example, tracking over 5,000 residents of Framingham, Massachusetts, to identify major cardiovascular disease risk factors. The remaining 75% of trials test medical interventions, with about 40% focused on drugs, medications, or vaccines, and 10% on medical devices such as implants and surgical instruments.

Drug development typically involves several phases, each with distinct objectives. The initial phase tests safety and dosage in small groups to explore optimal dosing and short-term toxicity. If a safe dose range is identified, the trial progresses to Phase II, which evaluates effectiveness and side effects in larger groups, typically composed of subjects with the condition being addressed. This phase must demonstrate that the treatment yields clinically meaningful results to justify further investment in the trials.

Phase III trials compare the new treatment to a placebo, current standard care, or other treatment modalities in large populations. These high-stakes trials account for 50-70% of total clinical development costs, and only about one in three drugs advances to this phase. What appears promising in earlier testing may not translate to clinical benefit.

Once Phase III is completed and regulatory approval is obtained, Phase IV trials monitor the real-world use of the new drug, device, or intervention, utilizing observational data from medical records, registries, or adverse-event databases.

The role of volunteers in clinical trials is vital. Trials investigating interventions for specific conditions need to enroll patients with those conditions, while prevention trials may involve individuals at risk for those conditions. By assembling a representative group of volunteers, researchers can ensure that the results are applicable to the broader community.

Healthy volunteers also play a crucial role in clinical research. For most new medications, excluding those for cancer and certain toxic biologics, healthy individuals can participate in Phase I trials to establish safety profiles, determine appropriate dosing ranges, and study how drugs are absorbed and metabolized in the body. Their contributions provide essential baseline data that helps researchers distinguish drug effects from disease symptoms in patient populations.

Nearly 60% of healthy volunteers cite societal benefits as their primary motivation for participation, recognizing that their involvement accelerates medical advancements that will ultimately benefit future patients, including their loved ones. By volunteering before facing health challenges themselves, these individuals help establish safety standards that protect all future clinical trial participants and expedite the delivery of promising treatments to those in need.

Clinical trials should be viewed as a social good, essential to enhancing health, extending life, and alleviating the burdens of illness and disability. Increased knowledge and awareness of clinical trials can help individuals understand the true benefits and risks, make informed decisions about participation, and advocate for clinical research within their communities.

As Dr. Francis Collins, a distinguished physician-geneticist and former Director of the NIH, stated, “Signing up for a clinical trial may benefit medical research and help future generations. But it is not strictly an altruistic endeavor. In many instances, trial participants do gain personal advantages, such as improved disease outcomes or better health.”

Understanding clinical trials is crucial for fostering participation and advancing medical research that can lead to innovative treatments and improved health outcomes for all.

Deepanwita Dasgupta, diagnosed with subacute sclerosing panencephalitis after contracting measles at age five, highlights the severe long-term risks associated with the virus.

Deepanwita Dasgupta’s journey began when she was just five years old, playing at her home in Bangalore, India. Her parents noticed that she was stumbling more often, attributing the extra bumps and bruises to her active nature. They thought perhaps her shoes were ill-fitting.

Described by relatives as smart, affectionate, and occasionally mischievous, Deepanwita had a knack for technology, managing to find her favorite show, *Blippi*, on a phone before she even learned the alphabet. She was known for sneaking butter from the fridge for a quick taste.

However, her playful childhood took a drastic turn when her limbs began to jerk uncontrollably. A spinal tap revealed the presence of the measles virus in her cerebrospinal fluid. The virus, contracted during her infancy, had silently made its way to her brain. Now, at eight years old, Deepanwita is paralyzed and unable to speak.

Measles is notorious for causing a range of complications, from diarrhea to death, affecting approximately three in ten infected individuals, according to the Infectious Diseases Society of America. While some complications arise immediately, others may take weeks or even months to manifest. Deepanwita’s condition, known as subacute sclerosing panencephalitis (SSPE), typically takes years to develop.

“People think, ‘Oh, you know, if we get measles, then we’ll be fine, because I know my neighbor had it and they’re fine,’” said Yasmin Khakoo, a leading neurologist in New York City. Khakoo emphasized the dangers of measles, noting that a seven-year-old in South Carolina had to relearn how to walk due to brain swelling, another immediate complication of the virus. In some cases, measles can plant a ticking time bomb in the nervous system, allowing individuals to appear healthy for years before severe problems arise. While some patients may experience temporary disabilities, the condition is almost always fatal.

Before the widespread availability of effective vaccines, SSPE was a common complication in the U.S. In the 1960s, a doctor established a national registry for SSPE patients. Current estimates suggest that about one in 10,000 individuals who contract measles will develop SSPE, with the risk significantly elevated for those infected before the age of five. Countries where measles is endemic, such as India, continue to see regular cases.

As vaccination rates decline and measles outbreaks increase in the U.S., medical professionals are concerned that cases of SSPE will also rise. Since the beginning of 2025, the Centers for Disease Control and Prevention has reported over 3,500 measles cases, surpassing the total from the previous decade, predominantly among unvaccinated individuals, many of whom are children. Last year, a six-year-old in Connecticut was diagnosed with SSPE, and a school-aged child in California died from the condition after contracting measles as an infant.

“We are likely to see SSPE cases going forward, especially if we don’t get this under control,” warned Adam Ratner, a member of the American Academy of Pediatrics’ Committee on Infectious Diseases.

In response to growing concern, the Child Neurology Society published a video in January to educate U.S. clinicians about SSPE, and physicians who have encountered such cases are urging their colleagues to be vigilant.

“We don’t have a way of knowing who’s going to get it, and we don’t have a way of very effectively treating it,” said Aaron Nelson, a professor of neurology at New York University. “The one best thing that we can do, ideally, is to prevent children from having to go through it in the first place.”

The recommended two-dose measles vaccine significantly reduces the risk of contracting the virus, lowering it from 90% to just 3%, thereby decreasing the likelihood of developing SSPE. While the vaccine carries minor risks, such as febrile seizures and a bleeding condition, the risks associated with measles itself are far greater.

Deepanwita’s story is a poignant reminder of the potential consequences of measles. In 2022, she celebrated her fifth birthday, unaware that her health would soon take a tragic turn. At her eighth birthday gathering, Deepanwita, dressed in a pink eyelet dress and supported by a nasal tube, could only blink and move her eyes as she sat before two cakes she could not eat.

Roberto Cattaneo, a molecular biologist at the Mayo Clinic, has been studying SSPE for years. He recently utilized postmortem brain tissue to investigate how the measles virus spreads within the brain. Despite his research, he acknowledges that the exact mechanisms of the virus during the dormant period between initial infection and the onset of neurological symptoms remain largely unknown.

“The problem could be solved with vaccination,” Cattaneo stated, expressing frustration that such a preventable condition still exists. “The U.S. should have no cases of SSPE. It’s just painful.”

As the number of measles outbreaks rises globally, the situation remains dire, particularly in countries like India. In New Delhi, Sheffali Gulati, a pediatric neurologist, sees about ten new SSPE patients each year, referring to the condition as a “delayed echo” of measles outbreaks. The youngest patient she has treated was just three years old.

With families like Deepanwita’s facing the harsh realities of SSPE, the urgent need for vaccination and awareness has never been clearer. The long-term effects of measles can be devastating, and the medical community continues to advocate for prevention to protect future generations.

According to KFF Health News, the importance of vaccination cannot be overstated in the fight against measles and its severe complications.

Vitamin D supplements may reduce the risk of long COVID symptoms, such as fatigue and brain fog, according to a recent study conducted by researchers at Mass General Brigham.

A new study suggests that vitamin D supplements could play a role in alleviating long COVID symptoms, which persist after the initial infection. Researchers at Mass General Brigham investigated whether high doses of vitamin D could affect COVID-19 outcomes, particularly the risk of developing long COVID, a condition characterized by lingering symptoms such as fatigue, shortness of breath, and brain fog. The findings were published in The Journal of Nutrition.

The randomized clinical trial involved 1,747 adults who had recently tested positive for COVID-19, along with 277 members of their households. Participants were assigned to receive either vitamin D3 supplements or a placebo for a duration of four weeks.

Dr. JoAnn Manson, the senior author of the study and a physician at Mass General Brigham, highlighted the potential benefits of vitamin D supplementation for long-term symptoms. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson stated.

While the study found that vitamin D supplementation did not significantly alter short-term outcomes, such as symptom severity or the need for hospital visits, a closer examination of participants who adhered to the supplement regimen revealed a noteworthy difference in lingering symptoms. Approximately 21% of those who took vitamin D reported at least one ongoing symptom eight weeks after infection, compared to 25% of participants who received a placebo.

“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson remarked in a press release. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.

Manson explained that vitamin D may influence longer-term complications due to its role in regulating inflammation within the body. However, the researchers acknowledged several limitations in the trial. The study had to be conducted remotely during the pandemic, and participants began taking vitamin D several days after their COVID diagnosis.

Ideally, Manson noted, supplementation should commence before infection or immediately following diagnosis. She emphasized the need for larger studies to confirm whether vitamin D could effectively reduce the risk or severity of long COVID symptoms.

Researchers are planning additional trials to further explore the potential of vitamin D supplementation in treating individuals already experiencing long COVID.

These findings provide a promising avenue for future research and may offer hope for those grappling with the long-term effects of COVID-19, according to Fox News.

A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.

Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).

The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.

Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”

This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.

However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.

Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.

Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.

Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.

As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.

According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.

Compounds in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease, a common chronic liver condition affecting many adults worldwide.

Research from the Hebrew University of Jerusalem suggests that compounds found in cannabis could pave the way for innovative treatments for the world’s most prevalent chronic liver disorder. The study, published in the British Journal of Pharmacology, highlights the potential of cannabidiol (CBD) and cannabigerol (CBG) in reducing liver fat and enhancing metabolic health in experimental models.

CBD is the more extensively researched non-intoxicating cannabinoid, while CBG serves as a precursor cannabinoid from which CBD is derived. Unlike THC, the primary psychoactive component of cannabis, both CBD and CBG do not induce a “high,” making them promising candidates for long-term medical applications.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently impacts approximately one-third of the global adult population, as indicated by health data. This condition is closely associated with obesity and insulin resistance, yet there are few approved pharmaceutical treatments available. Consequently, patients often rely on challenging lifestyle changes to manage their condition.

Lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, stated, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”

The research emphasizes a process known as “metabolic remodeling,” where the cannabis compounds create a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells. This energy reserve enables the liver to function more effectively under the stress of a high-fat diet, an unexpected finding noted by the research team.

Additionally, the study revealed that CBD and CBG restored the activity of “cellular cleaning crews,” known as cathepsins. These enzymes operate within the cell’s recycling centers to break down harmful fats and waste. As a result, the liver became more adept at clearing dangerous lipids, including triglycerides and ceramides, which are known to cause inflammation.

While both CBD and CBG demonstrated effectiveness, CBG yielded more pronounced results in specific areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol, and improving insulin sensitivity. The researchers believe this study opens new avenues for utilizing plant-based compounds to treat metabolic diseases by focusing on cellular energy management and waste disposal.

Despite these promising findings, the research team cautioned that the study was conducted in a controlled experimental setting. Further clinical trials are essential to ascertain the appropriate application of these compounds for human patients.

Recent studies have also raised concerns regarding the use of cannabis as a medical treatment. A major analysis published in JAMA examined over 2,500 scientific papers from the past 15 years, including reviews, clinical trials, and guidelines related to medical marijuana. This review underscored significant discrepancies between public perception and scientific evidence regarding the effectiveness of cannabis for various medical conditions.

The researchers concluded that only a limited number of conditions have clear, well-established benefits from cannabinoid therapies supported by high-quality clinical data. “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” noted Dr. Alex Dimitriu, who is double board-certified in psychiatry and sleep medicine. He emphasized that this study illustrates the reality that cannabis is not a universal remedy.

The strongest evidence currently supports FDA-approved cannabinoid medications for treating specific conditions, including appetite loss related to HIV/AIDS, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.

Individuals interested in exploring marijuana for medical purposes are encouraged to consult with a healthcare provider to discuss potential risks and benefits, ensuring informed decision-making regarding their health.

According to Fox News, the implications of this research could significantly impact the future treatment landscape for liver diseases.

Recent studies indicate that GLP-1 drugs, including Ozempic and Wegovy, may increase fracture risk and osteoporosis in older adults with Type 2 diabetes, prompting calls for closer monitoring of bone health.

A new study suggests that GLP-1 medications, such as Ozempic and Wegovy, may elevate the risk of fractures by 11% in adults aged 65 and older who have Type 2 diabetes, compared to those using other diabetes treatments.

These GLP-1 drugs have revolutionized the management of Type 2 diabetes and obesity, but recent findings indicate that healthcare providers should be more vigilant regarding bone health in older patients prescribed these medications. A study published in February in the Journal of Clinical Endocrinology & Metabolism revealed that older adults with Type 2 diabetes who began using GLP-1 medications experienced a statistically significant increase in the risk of fragility fractures.

Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author, emphasized that while an 11% increase may seem modest, it is significant for a vulnerable population. “Both older age and Type 2 diabetes are independent risk factors for fragility fractures,” she stated. “This is a population that deserves special attention.”

Fragility fractures are typically caused by minor falls or routine activities and are often associated with osteoporosis. Such fractures can lead to hospitalization, loss of independence, and even increased mortality among older adults, according to Dr. Kasher Meron.

The study monitored over 46,000 adults aged 65 and older for nearly three years. After making necessary adjustments, researchers found that those using GLP-1 medications had a modest but statistically significant increase in fracture risk.

Previous studies involving younger patients using older GLP-1 medications did not indicate an increased fracture risk. However, the newer and more potent versions are now commonly prescribed to older adults, which alters the risk landscape. “In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Dr. Kasher Meron noted.

It is important to highlight that the study was observational, indicating an association rather than causation. Researchers could not ascertain whether the increased risk was due to weight loss, dietary changes, muscle loss, or a direct effect on bone health.

Despite these findings, Dr. Kasher Meron advocates for assessing bone health before initiating GLP-1 medications in older patients rather than treating it as an afterthought. The study’s results coincide with additional research presented at the American Academy of Orthopaedic Surgeons’ annual meeting, which raised further concerns regarding bone health.

In an analysis of over 146,000 adults with obesity and Type 2 diabetes, those using GLP-1 medications were found to have a 29% higher relative risk of developing osteoporosis over five years compared to nonusers. Additionally, rates of gout were slightly elevated, affecting 7.4% of GLP-1 users versus 6.6% of nonusers, representing a 12% relative increase. Osteomalacia, a condition characterized by softening of the bones, was rare but occurred approximately twice as often in GLP-1 users, according to the study, which has not yet undergone peer review.

Experts suggest several mechanisms may contribute to these findings. GLP-1 medications suppress appetite and can lead to rapid weight loss, which is known to reduce bone density. This reduction occurs partly because less mechanical load is placed on the skeleton. Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, likened this phenomenon to astronauts experiencing low bone density after extended periods in a zero-gravity environment.

Moreover, a decrease in caloric intake may result in lower consumption of calcium, vitamin D, and protein—nutrients essential for maintaining bone strength. Rapid weight loss can also temporarily elevate uric acid levels, a byproduct of tissue breakdown, potentially explaining the rise in gout cases.

Despite these concerns, experts caution against discouraging the appropriate use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. In addition to bone density screenings, experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss.

A spokesperson for Novo Nordisk, the manufacturer of GLP-1 medications, stated that the company prioritizes patient safety and collaborates closely with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for Novo Nordisk, emphasized that the known risks and benefits of these drugs are reflected in the current FDA-approved labeling. She noted that semaglutide, one of the GLP-1 medications, has shown cardiovascular, kidney, and liver benefits when used under medical supervision.

“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.

These findings underscore the need for healthcare providers to closely monitor bone health in older adults prescribed GLP-1 medications, ensuring that the benefits of these treatments are balanced with potential risks.

According to Fox News Digital, the implications of these studies are significant for the management of diabetes and obesity in older populations.

New research suggests that GLP-1 weight-loss drugs may significantly reduce complications after heart attacks by improving blood flow to heart tissue.

Groundbreaking research indicates that a popular class of weight-loss drugs could play a crucial role in preventing life-threatening heart complications by reopening blocked blood vessels following heart attacks. The study, published this week in Nature Communications, was conducted by researchers from the University of Bristol and University College London.

The research identifies a biological signaling pathway involving the brain, gut, and heart, which may explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—help protect heart tissue from a condition known as “no-reflow.” This condition occurs when tiny blood vessels within the heart muscle remain constricted even after the main artery has been cleared during emergency treatment.

Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, highlighted the significance of the findings. “In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” she stated in a press release. “This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.” The lack of blood flow can increase the risk of heart failure and death within a year, but GLP-1 medications may offer a preventive solution.

The study reveals that when the GLP-1 hormone is released in the gut or administered as a medication, it sends signals to the brain. The brain, in turn, signals the heart to activate specific potassium channels in tiny cells known as pericytes. When these channels open, the pericytes relax, allowing small blood vessels, or capillaries, to widen and improve blood flow to the heart muscle.

Using animal models and cellular imaging, the researchers tracked how GLP-1 interacts with heart tissue. They discovered that when potassium channels were removed, the protective effects of the drugs on the heart were lost, confirming the channels’ critical role in this process.

The findings suggest that existing GLP-1 medications, which are already prescribed for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to minimize tissue damage.

However, the researchers acknowledged several limitations in their study, including its reliance on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Moreover, while the study emphasizes the drug’s immediate benefits during a heart attack, it does not clarify whether long-term use of the medication provides any pre-existing level of protection.

This research was primarily funded by the British Heart Foundation, underscoring the potential implications for future heart attack treatments.

According to Fox News, the study opens new avenues for understanding how existing medications can be utilized to enhance heart health and reduce complications following cardiac events.

Researchers have discovered that levetiracetam, a decades-old seizure medication, may prevent the progression of Alzheimer’s disease if administered years before symptoms manifest.

A promising breakthrough in Alzheimer’s prevention has emerged from a recent study suggesting that levetiracetam, a medication traditionally used to treat seizures, may help halt the disease’s progression. Originally approved by the FDA in November 1999 under the brand name Keppra, levetiracetam is primarily prescribed for partial-onset seizures in adults, with its use later expanding to include children and various seizure types.

Researchers at Northwestern University have found that levetiracetam can prevent the formation of toxic amyloid beta peptides, which are small protein fragments commonly associated with Alzheimer’s disease. The study, published in Science Translational Medicine, revealed that the medication effectively inhibited the formation of amyloid-beta 42 in both animal models and cultured human neurons. This effect was also observed in post-mortem brain tissue from individuals with Down syndrome, a group at heightened risk for developing Alzheimer’s.

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” said Jeffrey Savas, the study’s corresponding author and an associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine. “Our new results uncovered new biology while also opening doors for new drug targets.”

Savas explained that the brain is better equipped to avoid the pathways that produce toxic amyloid-beta 42 proteins during younger years. However, as individuals age, this ability diminishes. “This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he noted. This accumulation can lead to the formation of tau tangles—abnormal clumps of protein inside brain neurons—which can ultimately kill brain cells, trigger neuroinflammation, and result in dementia.

For levetiracetam to serve as an effective Alzheimer’s preventive, high-risk individuals would need to begin treatment “very, very early,” potentially up to 20 years before elevated levels of amyloid-beta 42 are detected. “You couldn’t take this when you already have dementia because the brain has already undergone a number of irreversible changes and a lot of cell death,” Savas cautioned.

The research team also analyzed existing clinical data to assess whether Alzheimer’s patients taking levetiracetam experienced a slower cognitive decline. They found that these patients had a “significant delay” in the time from cognitive decline to death compared to those not on the medication. “Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas stated.

Looking ahead, the research team aims to recruit individuals with genetic forms of Alzheimer’s for further testing. However, the study does have limitations, including its reliance on animal models and cultured cells, with no human trials conducted to date. As the study was observational, it cannot definitively prove that levetiracetam caused the prevention of toxic brain proteins.

Savas acknowledged that while levetiracetam shows promise, it is not without its drawbacks. The medication breaks down in the body relatively quickly, prompting the research team to work on developing a “better version” that would have a longer duration of action and more effectively target the mechanism responsible for preventing plaque production.

Common side effects of levetiracetam include drowsiness, weakness, dizziness, irritability, headache, loss of appetite, and nasal congestion. The medication has also been associated with potential mood and behavior changes, such as anxiety, depression, agitation, and aggression. In rare cases, it may lead to severe allergic reactions, skin reactions, blood disorders, and suicidal ideation.

Funding for this study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund. For further details, Fox News Digital reached out to both the drug manufacturer and the researchers for additional comments.

Experts caution individuals with diabetes to be vigilant about certain supplements that may adversely affect blood sugar levels and interact with medications.

Health experts are urging individuals with diabetes to exercise caution when considering dietary supplements, as some may pose significant risks by affecting blood sugar levels or interacting negatively with prescribed medications.

Surveys indicate that approximately 75% of U.S. adults have used dietary supplements, with 58% reporting usage within the past 30 days. However, experts emphasize that certain groups, particularly those with diabetes, should be particularly careful.

Dietary supplements encompass a wide range of products, including vitamins, minerals, herbs, amino acids, and probiotics, all designed to fill nutritional gaps and promote overall wellness. Some supplements target specific health functions, such as immune support, muscle recovery, and bone health.

Unlike prescription medications and over-the-counter drugs, dietary supplements are not typically approved by the Food and Drug Administration (FDA) before they hit the market. However, the FDA does regulate these products and can take action against those deemed unsafe or misbranded.

According to the National Institutes of Health (NIH), several supplements may pose serious health risks for individuals with diabetes. Dawn Menning, a registered dietitian and certified diabetes care and education specialist based in California, highlights St. John’s Wort as a supplement to avoid. While it is often marketed as a natural remedy for mild to moderate depression, it can interfere with diabetes medications by altering how the body metabolizes them.

“This can make medications less effective and complicate blood sugar management,” Menning explained. Although some claim that St. John’s Wort can help regulate blood sugar in individuals with type 2 diabetes, the evidence supporting this is limited and mixed.

Menning warns that combining this supplement with insulin or oral diabetes medications may increase the risk of hypoglycemia, a condition characterized by dangerously low blood sugar levels that can lead to dizziness, fatigue, and fainting.

Another supplement of concern is high-dose niacin, which is sometimes used to manage cholesterol levels. However, Menning cautions that it can significantly raise blood sugar levels, making it difficult to maintain an optimal A1c range.

Asian ginseng is often associated with increased energy, focus, and immune health. While it may offer some benefits for individuals with prediabetes and diabetes, there is evidence suggesting that it could lower blood sugar levels when taken alongside diabetes medications.

Jordan Hill, a registered dietitian with Top Nutrition Coaching in Colorado, advises against β-carotene supplementation for people with diabetes. The American Diabetes Association has linked this supplement to increased risks of lung cancer and cardiovascular mortality.

Cinnamon, frequently promoted for diabetes management and weight loss, has shown potential in reducing blood sugar and lowering insulin resistance. However, excessive consumption can lead to hypoglycemia, as well as liver damage due to a compound called coumarin found in cinnamon.

Oral aloe vera is another supplement that has gained popularity for its purported benefits for diabetes and weight loss. However, when combined with diabetes medications, it may cause blood sugar levels to drop too low, increasing the risk of hypoglycemia. Gastrointestinal side effects are also a concern with aloe vera.

Menning notes that for most supplements, there is insufficient evidence to support any beneficial effects on diabetes or its complications. The American Diabetes Standards of Care state that “without underlying deficiency, there are no benefits from herbal or nonherbal (i.e., vitamin or mineral) supplementation for people with diabetes.”

Furthermore, the American Association of Clinical Endocrinology advises caution with all unregulated nutritional supplements due to their inconsistent composition, quality, and potential for harm.

Experts recommend consulting with a healthcare provider before starting any supplement regimen to better understand how it may impact blood sugar levels, medications, or overall diabetes management.

For more information on the risks associated with dietary supplements for people with diabetes, refer to the National Institutes of Health.

A newly discovered virus within gut bacteria may be linked to an increased risk of colorectal cancer, offering new insights into the disease’s development, according to recent research.

Scientists in Denmark have identified a previously unknown virus residing in the gut bacterium Bacteroides fragilis, which may be associated with the development of colorectal cancer. The study, published in *Communications Medicine* earlier this month, reveals that patients diagnosed with colorectal cancer are approximately twice as likely to carry this virus compared to individuals without the disease.

Dr. Flemming Damgaard, PhD, from the Department of Clinical Microbiology at Odense University Hospital and the University of Southern Denmark, emphasized the significance of microorganisms in relation to human health. “These findings highlight the importance of the microorganisms in the gut and their relation to our health,” he stated. “If we want to understand the full picture, we need to look deep into their genetic material.”

For years, medical professionals have noted a higher prevalence of Bacteroides fragilis in colorectal cancer patients. However, since this bacterium is also commonly found in healthy individuals, the reasons for its harmful effects in certain cases remained unclear. This prompted researchers to investigate subtle genetic variations within the bacteria, leading to an unexpected discovery.

“We were very surprised to find a whole virus inside the bacteria from the colorectal cancer patients,” Damgaard remarked. “That was not something we expected when we started our study.”

The identified virus, classified as a bacteriophage, specifically infects bacteria rather than human cells. Notably, this viral type had not been documented prior to this research. The study involved analyzing stool samples from 877 individuals across Europe, the United States, and Asia, revealing that colorectal cancer patients were about twice as likely to carry traces of the virus compared to their cancer-free counterparts.

While the findings indicate a strong statistical association, researchers caution that the study does not establish a causal link between the virus and colorectal cancer. “The major limitation is that we still don’t know why the virus is linked to colorectal cancer,” co-author Ulrik Stenz Justesen explained. “But we are already continuing our research.”

The research team is currently conducting laboratory experiments and animal studies to explore whether the virus influences the behavior of Bacteroides fragilis in a manner that could contribute to cancer development.

Studies have shown that the human body is home to roughly as many microbial cells as human cells, highlighting the intricate relationship between microbes and overall health. “Our understanding of [microbial cells] is still in its infancy,” Damgaard noted. “There are many health-related discoveries to be made in the human microbiota.”

Colorectal cancer ranks among the leading causes of cancer-related deaths globally, according to the World Health Organization. The disease has gained increased visibility due to the deaths of several high-profile individuals, including James Van Der Beek, Catherine O’Hara, Kirstie Alley, Pelé, and Chadwick Boseman, underscoring its impact across various age groups.

While diet and lifestyle factors are significant contributors to colorectal cancer risk, researchers believe that gut bacteria may also play a crucial role. Current screening methods for colorectal cancer include stool tests that detect hidden blood and colonoscopies. In the future, researchers suggest it may be possible to test stool samples for viral markers similar to those identified in this study.

The researchers pointed to cervical cancer as an example of how recognizing a viral cause can enhance prevention efforts. Following the link between HPV and cervical cancer, vaccination programs have significantly reduced new cases. Although it is premature to draw direct comparisons, the researchers remain hopeful that colorectal cancer could follow a similar trajectory if a definitive viral role is established.

“It is too early to act,” Damgaard cautioned. “We have a lot of hope, and that is what we want people to have at this point,” he concluded.

According to Fox News Digital, this research opens new avenues for understanding the complexities of colorectal cancer and the potential role of viruses within the gut microbiome.